Aptar Pharma dose indicator selected for new asthma combination therapy

摘要

Aptar Pharma, developer and manufacturer of nasal and pulmonary drug delivery devices, has developed a customized Dose indicator for Flutiform~®, a SkyePharma product licensed to Mundipharma Intl. Corp. Ltd. in Europe. Flutiform is a combination of fluticasone propionate (fluticasone), an inhaled cortico-steroid (ICS), and formoterol fumarate (for-moterol), a long-acting beta2-agonist (laba). It is indicated for the maintenance treatment of asthma in patients aged 12 years and over, and in adults whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting beta2-agonist (SABA), and in those patients who are already receiving treatment with both an ICS and LABA.